This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0148607108322402v1 32/5/509    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Heyland, D. K. Articles by Wong, H. Search for Related Content PubMed PubMed Citation Articles by Heyland, D. K. Articles by Wong, H. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Antioxidants Dietary Supplements Hazardous Substances DB ZINC COMPOUNDS ZINC, ELEMENTAL Social Bookmarking                         What's this?

Zinc Supplementation in Critically Ill Patients: A Key Pharmaconutrient?

¹ KGH/Queen's University
² Children's Hospital and Research Centre
³ Cincinnati Children's Hospital Medical Centre and Children's Research Foundation

^* To whom correspondence should be addressed. E-mail: dkh2{at}post.queensu.ca.

	Abstract

The purpose of the present paper is to provide a rationale for zinc supplementation as a potential therapeutic agent in critically ill patients by describing its role in health and disease, conducting a systematic review of current randomized trials in critical care, considering optimum route and dose of administration, and making recommendations for future research. Normal zinc homeostasis is required for a functional immune system, adequate antioxidant capacity, glucose homeostasis, and wound healing. In addition, zinc is a required cofactor for many enzymes, transcription factors, and replication factors. In non–critically ill patients, zinc supplementation has been associated with an improvement in markers of immune function. In critically ill patients, only 4 randomized trials have examined the effect of zinc supplementation on clinical outcomes. When all 4 studies were aggregated, zinc supplementation was associated with a nonsignificant reduction in mortality (relative risk = 0.63, 95% confidence intervals 0.25-1.59, P = .33) and length of stay in intensive care (-0.35 days, -0.85 to 0.15; P = .17). Thus, because of the paucity of clinical data, there is inadequate evidence to recommend the routine use of high-dose zinc supplementation in the critically ill. A first step would be to determine the optimal dose that has a maximal positive effect on underlying inflammatory, immunologic, and metabolic processes yet is safe and tolerated by critically ill patients. Subsequently, large, rigorously designed, randomized trials are required to elucidate the efficacy of such doses of zinc supplementation in this patient population.

First published on July 31, 2008, doi:10.1177/0148607108322402

Journal of Parenteral and Enteral Nutrition 2008;32:509.

A more recent version of this article appeared on September 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. M. Berger Zinc: A Key Pharmaconutrient in Critically Ill Patients? JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 582 - 584. [Full Text] [PDF]

				J. A. Carcillo How Should We Nourish Our Sickest Children? JPEN J Parenter Enteral Nutr, September 1, 2008; 32(5): 584 - 585. [Full Text] [PDF]